Rani Therapeutics reprices stock options for executives to $2.84 per share

Rani Therapeutics Holdings, Inc.

Board approved reducing exercise price of certain outstanding options to $2.84 per share (closing price on Dec 16, 2023).
CEO Talat Imran: 936,444 options repriced from $5.44-$19.56; CFO Svai Sanford: 313,558 options from $5.44-$13.21.
CSO Mir Hashim: 328,374 options repriced from $5.44-$13.21; all options retain original vesting schedules and expiration dates.
Repricing covers employees, named executive officers, consultants, and non-employee directors; no other terms modified.
Board determined repricing best for retention and incentivization without cash outlay or additional equity dilution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.